GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (XBUL:NOV) » Definitions » Cash Flow from Financing

Novo Nordisk AS (XBUL:NOV) Cash Flow from Financing : лв-10,533 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Novo Nordisk AS Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2024, Novo Nordisk AS paid лв666 Mil more to buy back shares than it received from issuing new shares. It spent лв114 Mil paying down its debt. It paid лв0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent лв4,318 Mil paying cash dividends to shareholders. It received лв0 Mil on other financial activities. In all, Novo Nordisk AS spent лв5,098 Mil on financial activities for the three months ended in Sep. 2024.


Novo Nordisk AS Cash Flow from Financing Historical Data

The historical data trend for Novo Nordisk AS's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Cash Flow from Financing Chart

Novo Nordisk AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9,824.28 -9,814.07 -7,210.31 -13,728.19 -17,199.97

Novo Nordisk AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,282.72 -2,754.91 -7,158.49 4,478.58 -5,098.31

Novo Nordisk AS Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Novo Nordisk AS's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Novo Nordisk AS's Cash from Financing for the quarter that ended in Sep. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was лв-10,533 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novo Nordisk AS  (XBUL:NOV) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Novo Nordisk AS's issuance of stock for the three months ended in Sep. 2024 was лв0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Novo Nordisk AS's repurchase of stock for the three months ended in Sep. 2024 was лв-666 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Novo Nordisk AS's net issuance of debt for the three months ended in Sep. 2024 was лв-114 Mil. Novo Nordisk AS spent лв114 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Novo Nordisk AS's net issuance of preferred for the three months ended in Sep. 2024 was лв0 Mil. Novo Nordisk AS paid лв0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Novo Nordisk AS's cash flow for dividends for the three months ended in Sep. 2024 was лв-4,318 Mil. Novo Nordisk AS spent лв4,318 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Novo Nordisk AS's other financing for the three months ended in Sep. 2024 was лв0 Mil. Novo Nordisk AS received лв0 Mil on other financial activities.


Novo Nordisk AS Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk AS Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.